Answers are grounded in this paper and cite their sources.
Objective Dysregulation of cell-cycle control mechanisms plays an important role in the development of many cancers, including cervical cancer. After the role of CDK 4/6 in cell cycle control and carcinogenesis was elucidated, CDK 4/6 inhibitors were developed. Ribociclib is a selective CDK4/6 inhibitor, and although its activity has been investigated in several malignancies, its potential role in cervical cancer remains incompletely defined. This study aimed to evaluate the chemosensitizing effects of ribociclib when combined with cisplatin and paclitaxel in a single human papillomavirus type 18 (HPV18)-positive cervical cancer cell line. Material and Methods For the experimental model, only the HPV18-positive human cervical adenocarcinoma-derived HeLa cell line (ATCC CCL-2) was used. Cells were treated for 24 hours with ribociclib (25 µM), cisplatin (100 µM) plus paclitaxel (2 µM), or cisplatin (100 µM) plus paclitaxel (2 µM) plus ribociclib (25 µM). Untreated cells served as controls. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Markers of angiogenesis, proliferation, apoptosis, and metastatic behavior were evaluated by immunocytochemical staining for VEGF, CDK4, CDK6, Ki-67, Bax, Bcl-2, caspase-3, E-cadherin, vimentin, fibronectin, and MMP-9. Results After 24 hours, cell viability was 48% in the cisplatin plus paclitaxel group and 55% in the cisplatin plus paclitaxel plus ribociclib group. Thus, the addition of ribociclib did not further reduce cell viability compared with chemotherapy alone. Addition of ribociclib to chemotherapy significantly reduced Bcl-2, vimentin, and MMP-9 expression and increased caspase-3 expression compared with chemotherapy alone. No significant additional reductions in VEGF or Ki-67, nor significant additional increases in Bax or E-cadherin, were observed with ribociclib. Conclusion In this single-cell-line, 24-hour in vitro model, ribociclib combined with cisplatin and paclitaxel was associated with changes in selected markers of apoptosis and metastatic behavior, despite not producing lower MTT-measured cell viability than chemotherapy alone. These findings constitute hypothesis-generating preclinical evidence and require validation in additional HPV18-positive and other cervical cancer models, in animal studies, and, ultimately, in clinical studies before any translational conclusions can be drawn.
No takes yet. Share an insight, caveat, or question.
Davarcı et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: